10.1111/nan.12758
Publishers page: http://dx.doi.org/10.1111/nan.12758
<http://dx.doi.org/10.1111/nan.12758>

Please note:
Changes made as a result of publishing processes such as copy-editing, typesetting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You
are advised to consult the publisher’s version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.
A systems-level analysis highlights microglial activation as a modifying factor in common epilepsies

Andre Altmann1 | Mina Ryten2 | Martina Di Nunzio3 | Teresa Ravizza3 |
Daniele Tolomeo3 | Regina H. Reynolds2 | Alyma Somani4 | Marco Bacigaluppi5 |
Valentina Iori3 | Edoardo Micotti3 | Rossella Di Sapià3 | Milica Cerovic3 |
Eleonora Palma6 | Gabriele Ruffolo6 | Juan A. Botía2,7 | Julie Absi8 |
Saud Alhusaini9,10 | Marina K. M. Alvim11 | Pia Auvinen12,13 | Nuria Bargallo14,15 |
Emanuele Bartolini16,17 | Benjamin Bender18 | Felipe P. G. Bergo11 |
Tauana Bernardes11 | Andrea Bernasconi19 | Neda Bernasconi19 |
Boris C. Bernhardt20 | Karen Blackmon21 | Barbara Braga11 |
Maria Eugenia Caligiuri22 | Anna Calvo14 | Chad Carlson23,24 | Sarah J. A. Carr25 |
Gianpiero L. Cavallieri9,26 | Fernando Cendes11 | Jian Chen27 | Shuai Chen28,29 |
Andrea Cherubini22 | Luis Concha30 | Philippe David8 | Norman Delanty9,26,31 |
Chantal Depondt32 | Orrin Devinsky33 | Colin P. Doherty26,34 | Martin Domin35 |
Niels K. Focke36,37 | Sonya Foley38 | Wendy Franca11 | Antonio Gambardella22,39 |
Renzio Guerrini16 | Khalid Hamandi38,40 | Derrek P. Hibar41 | Dmitry Isaev41 |
Graeme D. Jackson42,43 | Neda Jahanshad41 | Reetta Kälviäinen12,13 |
Simon S. Keller44 | Peter Kochunov45 | Raviteja Kotikalapudi18,35,36 |
Magdalena A. Kowalczyk42 | Ruben Kuzniecky46 | Patrick Kwan47 |
Angelo Labate22,39 | Soenke Langner35 | Matteo Lenge16 | Min Liu19 |
Pascal Martin36 | Mario Mascali14 | Stefano Meletti49 |
Marcia E. Morita-Sherman11,50 | Terence J. O’Brien47,51 | Jose C. Pariente14 |
Mark P. Richardson25,52 | Raul Rodriguez-Cruces20,30 | Christian Rummel53 |
Taaivi Saavalainen13,54 | Mira K. Semmelroch42,43 | Mariasavina Severino55 |
Pasquale Striano56 | Thomas Thesen23 | Rhys H. Thomas57 | Manuela Tondelli50 |
Domenico Tortora55 | Anna Elisabetta Vaudano49 | Lucy Vivash47,58 |
Felix von Podewils59 | Jan Wagner60 | Bernd Weber61 | Roland Wiest53 |
Clarissa L. Yasuda11 | Guohao Zhang62 | Junsong Zhang28,29 | ENIGMA-Epilepsy |
Working Group | Costin Leu63,64,65 | Andreja Avbersek64 | EpiPGX Consortium |
Maria Thom4,65 | Christopher D. Whelan9,41 | Paul Thompson41 |

Andre Altmann, Mina Ryten and Martina Di Nunzio contributed equally.
Carrie R. McDonald 66,67 | Annamaria Vezzani 3 | Sanjay M. Sisodiya 65,68

1Centre for Medical Image Computing, University College London, London, UK
2Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK
3Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
4Division of Neuropathology, UCL Queen Square Institute of Neurology, London, UK
5Department of Neurology, San Raffaele Scientific Institute and Vita Salute San Raffaele University, Milan, Italy
6Department of Physiology and Pharmacology, Sapienza University of Rome, Rome, Italy
7Department of Radiology, Hôpital Erasme, Universite Libre de Bruxelles, Brussels, Belgium
8Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland
9Neurology Department, Yale University School of Medicine, New Haven, CT, USA
10Department of Neurology, University of Campinas, Campinas, Brazil
11Epilepsy Center, Department of Neurology, Kuopio University, Kuopio, Finland
12Institute of Clinical Medicine, Neurology, University of Eastern Finland, Kuopio, Finland
13Magnetic Resonance Image Core Facility, IDIBAPS, Barcelona, Spain
14Centre de Diagnostic Per la Imatge (CDIC), Hospital Clinic, Barcelona, Spain
15Pediatric Neurology Unit, Children’s Hospital A. Meyer-University of Florence, Florence, Italy
16Neurology Unit, USL Centro Toscana, Nuovo Ospedale Santo Stefano, Prato, Italy
17Department of Diagnostic and Interventional Neuroradiology, University of Tübingen, Tübingen, Germany
18Neuroimaging of Epilepsy Laboratory, Montreal Neurological Institute and Hospital, McGill University, Montreal, Quebec, Canada
19Multimodal Imaging and Connectome Analysis Lab, Montreal Neurological Institute and Hospital, McGill University, Montreal, Quebec, Canada
20Psychiatry and Psychology, Mayo Clinic, Jacksonville, FL, USA
21Neuroscience Research Center, Department of Medical and Surgical Sciences, University “Magna Græcia” of Catanzaro, Catanzaro, Italy
22Comprehensive Epilepsy Center, Department of Neurology, New York University School of Medicine, New York, New York, USA
23Department of Neurology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
24Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
25FutureNeuro Research Centre, RCSI, Dublin, Ireland
26Department of Computer Science and Engineering, The Ohio State University, Columbus, Ohio, USA
27Cognitive Science Department, Xiamen University, Xiamen, China
28Functional Imaging Unit, Institute of Diagnostic Radiology and Neuroradiology, University Medicine Greifswald, Greifswald, Germany
29Department of Neuroradiology, University Medicine Göttingen, Göttingen, Germany
30The Welsh Epilepsy Unit, Department of Neurology, University Hospital of Wales, Cardiff, UK
31Institute of Neurology, University “Magna Græcia”, Catanzaro, Italy
32Cardiff University Brain Research Imaging Centre, School of Psychology, Cardiff University, Cardiff, UK
33Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, University of Southern California, Los Angeles, California, USA
34Florey Institute of Neuroscience and Mental Health, Austin Campus, Melbourne, Victoria, Australia
35Florey Department of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Victoria, Australia
36Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK
37Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland, USA
38Department of Neurology, Zucker Hofstra School of Medicine, New York, New York, USA
39Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia
A systems-level analysis highlights microglial activation as a modifying factor in common epilepsies.

**Abstract**

**Aims:** The causes of distinct patterns of reduced cortical thickness in the common human epilepsies, detectable on neuroimaging and with important clinical consequences, are unknown. We investigated the underlying mechanisms of cortical thinning using a systems-level analysis.

**Methods:** Imaging-based cortical structural maps from a large-scale epilepsy neuroimaging study were overlaid with highly spatially resolved human brain gene expression data from the Allen Human Brain Atlas. Cell-type deconvolution, differential expression analysis and cell-type enrichment analyses were used to identify differences in cell-type distribution. These differences were followed up in post-mortem brain tissue from humans with epilepsy using Iba1 immunolabelling. Furthermore, to investigate a causal effect in cortical thinning, cell-type-specific depletion was used in a murine model of acquired epilepsy.

**Results:** We identified elevated fractions of microglia and endothelial cells in regions of reduced cortical thickness. Differentially expressed genes showed enrichment for microglial markers and, in particular, activated microglial states. Analysis of post-mortem brain tissue from humans with epilepsy confirmed excess activated microglia. In the murine model, transient depletion of activated microglia during the early phase of the disease development prevented cortical thinning and neuronal cell loss in the temporal cortex. Although the development of chronic seizures was unaffected, the epileptic mice with early depletion of activated microglia did not develop deficits in a non-spatial memory test seen in epileptic mice not depleted of microglia.
1 | INTRODUCTION

Significant progress is being made in understanding disease processes in the epilepsies. Many genetic variants causing or associated with rare and common epilepsies have been reported [1, 2], with discovery continuing apace [3]. Numerous direct structural causes of epilepsy have been revealed by brain magnetic resonance imaging (MRI). Several structural abnormalities are now themselves known to have a genetic basis [4]. As a result, the proportion of causally explicable epilepsies is growing rapidly. Conversely, the mechanisms whereby these identified causes promote epileptogenesis and seizures remain obscure for most human epilepsies. Moreover, beyond causation and epileptogenesis, the epilepsies involve many other processes: some lead to clinically apparent consequences, such as developmental delay or memory dysfunction, whereas others, without necessarily obvious symptoms, may be detected only on investigation—cerebellar atrophy is one example. The natural history of any given epilepsy need not be a single linear dynamic from causation to a unique, predictable, final outcome: for example, the epilepsies are associated with shortened longevity (even if seizures stop) [5] and increased risk of particular comorbidities [6]. Known causes per se may not explain all the observed outcomes, suggesting that many epilepsies could be conceptualised as intricate matrices of causation, processes and outcomes [7], with complex inter-dependencies, such as a likely link between reduction in cortical thickness and disease duration [8].

Through the ENIGMA-Epilepsy consortium, we recently showed that across a wide range of common human epilepsies, which are known to have both distinct and shared genetic architecture [2, 3, 9, 10], there are also shared, pan-syndrome, and distinct, syndrome-specific, regional patterns of altered cortical thickness and altered subcortical grey matter volumes [8]. The causes of the structural changes in these epilepsies are not known. The findings suggest that structural losses may reflect an initial insult, subsequent epileptogenesis or progressive neurodegeneration, or some combination, and show robustly that the common epilepsies cannot necessarily be considered entirely benign at the structural level. We sought to identify processes underlying the structural findings.

The pathophysiology of neurological disease has been successfully revealed using powerful combinations of brain MRI findings, regionalised brain-specific gene expression and gene co-expression networks, in a systems biology framework to implicate candidate genes [11–14]. Here, we used the findings from the in vivo ENIGMA-Epilepsy imaging study [8] in combination with the post-mortem atlas of gene expression in the brain from healthy subjects, curated by the Allen Institute [15, 16] to direct interrogation of regionalised brain cell-type composition and generic biological processes that might underlie thickness or volume reductions across the studied epilepsy syndromes. We hypothesised that this approach could suggest disease mechanisms causing the observed structural changes. We further explored the findings with a series of additional experiments in both human and animal tissues. We demonstrated experimentally in a murine model of acquired epilepsy that depletion of the implicated cell type, microglia, can successfully avert cortical thinning and the concomitant neuronal cell loss and cognitive deficit, without modifying spontaneous seizures. Microglia have been shown to have various roles in a few rare, severe human epilepsies. Our new results implicate microglia in the widespread, but largely unstudied, reduction in cortical thickness that accompanies the numerically far more important common human epilepsies and point to the potential for prevention of such thinning by manipulation of microglia.

2 | MATERIALS AND METHODS

In order to explore mechanisms underlying cortical thinning in the epilepsies, we designed the study as shown in Figure 1. We obtained statistical maps from a large structural MRI study comparing people with epilepsy to healthy controls conducted by the ENIGMA-Epilepsy consortium [8] (Table S1). To determine cell-type composition differences that spatially correlate with the reported structural changes on MRI, we used a healthy control dataset, the Allen Human Brain Atlas (AHBA), comprising densely sampled gene expression across the cortex [15, 16]. The statistical maps were mapped onto the AHBA using Montreal Neurological Institute (MNI) coordinates. This enabled us to
investigate how the spatial distribution of gene expression in the healthy brain correlates with regional vulnerability in the diseased brain. Our primary hypothesis was that cell types causing structural changes observed on human brain MRI could be identified using the design shown in Figure 1A. Briefly, cortical brain regions were classified as vulnerable to, or relatively protected from, cortical thinning based on the previous imaging results [8]. Then two complementary approaches were used to identify cell types with association to reduced cortical thickness: (i) AHBA microarray expression data were de-convolved into cell-type fractions, and these fractions were tested for differences between brain regions; (ii) a standard differential expression analysis was carried out for each gene expression probe, and cell types were identified using enrichment analyses (for details on pre-processing, atlas mapping, quality control and the statistical approach, see Supporting Information Methods, section A). The analysis code for the gene expression analyses is available (https://github.com/andrealtmann/AHBA_Epilepsy).

We hypothesised that cell types identified from the in silico analysis of data on the spatial distribution of gene expression in the brain from non-epileptic donors would also show compatible differences in spatial distribution in tissue samples obtained from people with epilepsy. Therefore, immunostaining of microglia in post-mortem human brain tissue was carried out to substantiate the cell-type findings from the in silico work. The human post-mortem cases were classified into different epilepsy groups and control groups according to clinical and pathology criteria. The final sample size was based on availability of tissues for certain epilepsies (as characterised by clinical data including electroencephalography [EEG] and MRI) and whether regional tissue paraffin-embedded block samples were available in each case from multiple brain regions (see Supporting Information Methods, section C). Briefly, the labelling index (LI) sums overall microglia presence in terms of cell bodies as well as microglial processes (as cell bodies may not be present in every section, but processes are likely to be important in microglial roles), overcoming issues of microglial

---

**FIGURE 1** Analysis overview. (A) The ENIGMA-Epilepsy study identified ‘vulnerable’ and ‘relatively protected’ brain regions indicated in red and blue, respectively (second column; top) [8]. Cortical samples of the AIBS dataset (purple dots; first column, bottom) were marked as either ‘vulnerable’ (red dots) or ‘relatively protected’ (blue dots) depending on their location (second column; middle). Brain cell-type fractions were estimated from the gene expression data, and the differential analysis showed an increased fraction of microglia and endothelial cells in ‘vulnerable’ compared with ‘relatively protected’ regions. Differential gene expression analysis between the two groups followed by pathway analysis confirmed the enrichment for marker genes for microglia as well as immune activation-related pathways. (B) LD score regression estimating the enrichment of immune response eQTL signatures in different epilepsy GWAS finds strong enrichment in disease severity (drug-resistant vs drug-susceptible) but not in disease risk (cases vs controls). eQTL, expression quantitative trait locus; GWAS, genome-wide association study; IFN, interferon; LD, linkage disequilibrium; LPS, lipopolysaccharide.
clustering, overlap and aggregation around vessels that can confound individual cell counts. LI also covers all microglial cell types regardless of morphology, size and shape. LI was measured across 14 regions of interest (ROIs) in post-mortem brain tissue derived from 55 individuals, comprising individuals with non-lesional epilepsy (EP-NL, n = 18), lesional epilepsy (EP-L, n = 21) and non-epilepsy controls (NEC, n = 16). No sample size calculations were performed because this was not a discovery sample, but a previous similar study of regional cortical pathology achieved a significant statistical result compared with controls with nine post-mortem cases, whereas this study included 55 individuals [17]. Staining was repeated on the same cases in different immunohistochemistry runs for comparison.

Further, in order to assess whether cortical thinning can be prevented by manipulating microglia, we used a well-established murine model of epilepsy induced by convulsive status epilepticus (SE) provoked by intra-amygdalar injection of kainic acid in C57/BL6N adult male mice (30 g; Charles River, Italy) [18–21]. This model mimics features of mesial temporal lobe epilepsy (MTLE) with hippocampal sclerosis, with neuronal damage also observed in extrahippocampal areas [19–21]. To explore the importance of microglia in brain structural changes and pathologic outcomes, mice were treated with the CSF1R inhibitor PLX3397 in a controlled experiment. We assessed the effect of PLX3397 treatment on cognitive performance using the novel object recognition test (NORT), regional brain volume estimates from post-mortem MRI, abundance of microglia and neurons quantified using immunohistochemistry and Nissl staining, respectively. The sample size was determined a priori based on previous experience with the same epilepsy model [18, 20]. A simple random allocation was applied to assign a subject to a particular experimental group.

Group 1: medicated diet (supplemented with PLX3397), n = 5 and placebo (non-medicated) diet, n = 5; Group 2: medicated diet (supplemented with PLX3397), n = 6 and placebo (non-medicated) diet, n = 5 (experimental design in Figure S1A). Respective sham mice (n = 8) were prepared for behavioural testing and post-mortem analyses. These groups were run 15 days apart. Group 3: placebo diet mice exposed to SE, n = 8 (run in parallel with Group 1, n = 4 and Group 2, n = 4) and respective sham mice, n = 8. Group 3 mice were prepared to compensate for potential dropouts during the longitudinal experiment (Figure 3C). Limited PLX3397-supplemented diet availability prevented further experiments. To verify the reproducibility of the experimental findings, we compared several EEG measures between the different placebo-diet mouse cohorts, namely, SE onset and duration, temporal distribution of spikes during SE, number and duration of spontaneous seizures. For all these measures, statistical analysis showed that replication was successful. The data were collected by anonymising samples, and the assessor was blinded to diagnosis (for both human tissue and experimental mouse model data). For detailed materials and methods and mouse treatment protocols, see Supporting Information Methods (section D).

<table>
<thead>
<tr>
<th>Cell type</th>
<th>T-value</th>
<th>P-value</th>
<th>P_{FDR}</th>
<th>P_{perm}</th>
</tr>
</thead>
<tbody>
<tr>
<td>Astrocytes</td>
<td>2.080608</td>
<td>0.037</td>
<td>0.043</td>
<td>0.17</td>
</tr>
<tr>
<td>Endothelial</td>
<td>4.426344</td>
<td>1.0 × 10^{-5}</td>
<td>7.67 × 10^{-5}</td>
<td>0.026</td>
</tr>
<tr>
<td>ExNeurons</td>
<td>-3.855666</td>
<td>1.15 × 10^{-4}</td>
<td>3.08 × 10^{-4}</td>
<td>0.051</td>
</tr>
<tr>
<td>InNeurons</td>
<td>0.684069</td>
<td>0.49</td>
<td>0.49</td>
<td>0.37</td>
</tr>
<tr>
<td>Microglia</td>
<td>4.081655</td>
<td>4.5 × 10^{-5}</td>
<td>1.79 × 10^{-4}</td>
<td>0.032</td>
</tr>
<tr>
<td>Oligodendrocytes</td>
<td>2.456355</td>
<td>0.014</td>
<td>0.019</td>
<td>0.053</td>
</tr>
<tr>
<td>OPC</td>
<td>2.758717</td>
<td>5.8 × 10^{-3}</td>
<td>0.014</td>
<td>0.068</td>
</tr>
<tr>
<td>Unknown</td>
<td>2.690987</td>
<td>0.007</td>
<td>0.011</td>
<td>0.066</td>
</tr>
</tbody>
</table>

Note: Columns represent the cell type, the t-value from the association analysis, the corresponding P-value and the corrected P-value using false discovery rate (FDR). The least column lists a P-value obtained from 1000 permutations of the vulnerable/protected status of 34 regions of interest in the left hemisphere.

Abbreviation: OPC, oligodendrocyte progenitor cell.
regional vulnerability in the broad spectrum of epilepsies, we focussed our analyses on the shared pan-syndrome MRI findings [8]. Of the 34 cortical regions in the left hemisphere profiled within the ENIGMA-Epilepsy dataset, eight were considered vulnerable to reduced cortical thickness, whereas 26 were considered relatively protected [8] (Table S1).

Using linear mixed effects models, we compared these two types of cortical region for significant differences in cell-type fractions, inferred from gene expression using Scaden [23]. We identified increased ratios of endothelial cells (T = 4.4; P = 1 \times 10^{-5}) and microglia (T = 4.1; P = 4.5 \times 10^{-5}) in vulnerable regions, along with a decreased ratio of excitatory neurons (T = -3.9; P = 1.2 \times 10^{-4}) in vulnerable regions (Table 1). We confirmed these cell-type enrichments by a complementary two-step approach. The first step was a gene-wise association screen, showing that, out of 14,138 tested genes, 3182 genes were more highly expressed in vulnerable regions (at P_{FDR} < 0.05) and 2223 genes were expressed significantly less in vulnerable regions (at P_{FDR} < 0.05; Dataset S1). In the second step, these gene-wise results were subject to threshold-free (i.e., not relying on lists of significantly differentially expressed genes) gene set enrichment analyses using cell-type-specific gene sets from different data sources (Dataset S2). This analysis confirmed the enrichment of endothelial cells and microglia in vulnerable regions and neurons in protected regions. We noted that both analyses provided qualitatively the same result when using all 1628 AHBA samples from both hemispheres, where 18 of 68 ROIs were considered vulnerable (Table S2; Figure S15). Thus, regions vulnerable to cortical thinning were characterised by elevated proportion of microglia and endothelial cells.

### 3.2 Selected processes and microglial signatures are implicated amongst genes associated with reduced cortical thickness

Using our gene-level association results, we next investigated the biological processes that could underpin regional differences in vulnerability to reduced cortical thickness in epilepsy. In the first instance, we investigated enrichment of differentially expressed genes in Gene Ontology (GO) terms and Kyoto Encyclopaedia of Genes and Genomes (KEGG) and REACTOME pathways using a threshold-free approach based on the area under the receiver operator characteristic curve (AUC) [24]. Amongst genes with higher expression in relatively protected cortical regions, the most significant terms we identified related to RNA processing (REACTOME: RNA polymerase II transcription, AUC = 0.429, P_{FDR} = 1.19 \times 10^{-11}) and synaptic function (GO: postsynaptic specialisation organisation, AUC = 0.270, P_{FDR} = 3.95 \times 10^{-4}; Dataset S3). Conversely, amongst genes with higher expression in vulnerable cortical regions, the most significant terms related to electron transport (GO: electron transport chain, AUC = 0.74, P_{FDR} = 3.45 \times 10^{-13}) and immune function and regulation (REACTOME: innate immune system, AUC = 0.59, P_{FDR} = 1.46 \times 10^{-15}; GO: antigen processing and presentation, AUC = 0.65, P_{FDR} = 7.98 \times 10^{-12}; Dataset S3), the latter being consistent with our results obtained using cell-specific gene sets. There was also strong enrichment for the KEGG pathways related to neurodegenerative diseases (Alzheimer’s disease: AUC = 0.65, P_{FDR} = 3.53 \times 10^{-6}; Parkinson’s disease: AUC = 0.75, P_{FDR} = 4.55 \times 10^{-12}; Huntington’s disease: AUC = 0.66, P_{FDR} = 1.80 \times 10^{-7}). Moreover, this approach also enabled us to obtain more specific process-related information and suggested the importance of the interferon gamma signalling pathway (GO: response to interferon gamma, AUC = 0.597, P_{FDR} = 1.42 \times 10^{-3}; GO: interferon gamma-mediated signalling pathway, AUC = 0.621, P_{FDR} = 6.71 \times 10^{-3}; Dataset S3).

A number of cell types showed enrichment in vulnerable regions. But both cell-type analysis and the observed pathway enrichments implicated microglia and immune processes, respectively, prompting us to investigate microglia in more detail, given existing evidence for a role for microglia in epilepsy [25] and in neurodegeneration in general [26]. More precisely, because microglia can exist in a range of activation states within the context of epilepsy [25], we sought to identify the microglial cell states of greatest importance in reduced cortical thickness. We collated gene signatures for distinct microglial states from the existing literature and also inferred signatures of microglial state through co-expression network analyses (see Supporting Information Methods, section A). Although there were significant overlaps in gene membership across the 16 microglial signatures used (Figure S2), each of the gene lists was distinct. We identified a significant enrichment for 13 of the 16 signatures with genes overexpressed in vulnerable cortex. This included the microglial signature generated by Srivastava et al. [27] (AUC = 0.68, P_{FDR} = 1.45 \times 10^{-12}; Dataset S4), which was positively correlated with seizure frequency in a particular mouse model of chronic epilepsy. Strong enrichments were also identified for an inferred human microglial signature enriched for type 1-like microglial markers (AUC = 0.73, P_{FDR} = 7.27 \times 10^{-18}; grey60; Dataset S4), as well as signatures for aged, late activation and de-activated microglia. However, we saw little evidence for enrichment within signatures of early activation (‘Early Response’ signature [28], AUC = 0.53, P_{FDR} = 0.062). Similar microglial states have recently been implicated in various forms of chronic neurodegeneration [28–30], but more data are needed to definitively determine whether similar underlying processes and microglial states are indeed involved.

### 3.3 Genetic evidence supports immune activation as a modifying, but not causal, factor in the common epilepsies

In the ENIGMA-Epilepsy imaging study, region-specific reduced cortical thickness across the common epilepsies was correlated with disease duration and age of onset of epilepsy [8]. Given that the analyses of gene expression data from healthy donors described above suggest the importance of microglia responses in vulnerability to reduced cortical thickness, we hypothesised that genetic variants affecting
microglial responses would also impact upon the severity of epilepsy. Although no microglial expression quantitative trait locus (eQTL) dataset exists to date, eQTL analyses have been performed using monocytes at rest, and also monocytes treated with interferon-γ (IFN-γ) or lipopolysaccharide (LPS) [31]. We postulated that these eQTLs would be enriched for heritability of risk loci for epilepsy that is drug resistant (one surrogate for disease severity) but not for epilepsy per se. To investigate this, we used genome-wide association study (GWAS) data on epilepsy susceptibility [2] and separate GWAS data on the phenotype of drug-resistant epilepsy from the EpiPGX consortium (www.epipgx.eu). Using linkage disequilibrium (LD) score regression, we sought enrichment in heritability for these phenotypes within state-specific monocyte eQTLs [31] (Supporting Information Methods, section B). We found no significant enrichment in the heritability of epilepsy in this form of annotation, suggesting that susceptibility to common epilepsies is less likely to be driven by immune processes (Figure 1B, Table 2). However, eQTLs regulating the vulnerability to common epilepsies is less likely to be driven by immune processes (Figure 1B, Table 2). However, eQTLs regulating the response to IFN-γ were highly enriched for drug-resistant epilepsy vs drug-responsive epilepsy loci ($P = 0.00045$; $P_{FDR} = 0.0095$, Table 2). This result was particularly striking given the small size of the EpiPGX drug-resistant epilepsy GWAS (2423 drug-resistant cases vs 1626 drug-responsive cases). Thus, we provide genetic evidence in support of microglial-mediated responses as a modifying factor in severity of epilepsy, but not its susceptibility.

### 3.4 Widespread regionalised over-representation of microglia is present in brain tissue from people with epilepsy

On the basis of the analyses of regional gene expression patterns in healthy brains above, we hypothesised that brain tissue from individuals with various forms of epilepsy would have regionalised higher densities of microglia as compared with tissue from non-epilepsy controls and that this would be apparent beyond the context of acute seizure activity. Using Iba1 immunolabelling, we found that single ramified microglia and processes were found throughout the cortex; scattered perivascular macrophages were also labelled (Figure 2A). Enlarged and more complex/branching microglia, focal aggregates and amoeboid/macrophage forms were noted in some ROIs (Figure 2A). Consistent with our hypothesis, the Iba1 LI was significantly higher in all epilepsy (EP-NL and EP-L together) than NEC for all ROIs ($P = 4.0 \times 10^{-13}$) and for both subgroup comparisons (EP-NL [$P = 3.7 \times 10^{-12}$] and EP-L [$P = 3.5 \times 10^{-13}$]) against NEC. Regional differences were noted within the epilepsy groups and for individual ROIs compared between epilepsy and control groups (see Figures 2 and S16 and Table S3). We noted that the Iba1 LI was similar across EP-NL, EP-L and NEC in BA17, as compared with pulvinar and BA22 where the Iba1 LI was higher in EP-NL and EP-L groups than in NEC. Thus, these results are consistent with the view that there is an over-representation of microglial footprint in brain tissue from people with chronic epilepsy and that such microglial responses may occur in a regionally specific manner. This observation was supported by evidence of region-specific microglia expansion in epileptic mice as reflected by the increased number of Iba1-positive cells in entorhinal cortex but not in perirhinal cortex (Figure S3). Moreover, in sham mice, we also observed that the temporal cortices have a higher microglia density than the hippocampus, denoting regionalised microglia enrichment at baseline (Figure S3).

### 3.5 Experimental evidence supports microglial activation as a modifying factor for cortical thickness in a mouse model of acquired epilepsy

The analyses so far have shown (i) elevated expression of microglia-related genes in brain regions, deemed ‘vulnerable’ from the ENIGMA-Epilepsy imaging study, in healthy brains and (ii) widespread regionalised over-representation of microglia in brain tissue from people with epilepsy compared with tissue from non-epileptic controls. To provide proof-of-concept evidence causally linking microglia activation to cortical thinning, we used a mouse model of acquired epilepsy where convulsive seizures originate and spread in the limbic system and also involve the neocortex [18–21]. Spontaneous seizures develop a few days after the acute insult (mean ± SEM, onset, 6.2 ± 0.5 days, $n = 21$ mice of Figure 3C) and recur for months (Figure S4B,C) and are drug resistant [20]. Microglia are

### Table 2

<table>
<thead>
<tr>
<th>eQTL type</th>
<th>GWAS (rows) in different epilepsy GWAS (columns)</th>
<th>Drug-resistant vs HC</th>
<th>Drug-resistant vs drug responders</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ILAE (epilepsy vs HC)</td>
<td>Drug-resistant vs HC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>$P$</td>
<td>$P_{FDR}$</td>
<td>$P$</td>
</tr>
<tr>
<td>Naïve monocytes</td>
<td>$8.73 \times 10^{-2}$</td>
<td>$1.63 \times 10^{-1}$</td>
<td>$3.43 \times 10^{-2}$</td>
</tr>
<tr>
<td>IFN-γ-treated</td>
<td>$1.56 \times 10^{-2}$</td>
<td>$8.12 \times 10^{-2}$</td>
<td>$5.09 \times 10^{-2}$</td>
</tr>
<tr>
<td>LPS-treated (2 h)</td>
<td>$1.43 \times 10^{-1}$</td>
<td>$2.32 \times 10^{-1}$</td>
<td>$2.70 \times 10^{-1}$</td>
</tr>
<tr>
<td>LPS24-treated (24 h)</td>
<td>$3.17 \times 10^{-2}$</td>
<td>$8.12 \times 10^{-2}$</td>
<td>$1.97 \times 10^{-2}$</td>
</tr>
</tbody>
</table>

Note: Bold font marks significant enrichments at $P_{FDR} < 0.05$.

Abbreviations: eQTL, expression quantitative trait locus; GWAS, genome-wide association study; HC, healthy controls; IFN-γ, interferon γ; ILAE, International League Against Epilepsy study (The International League Against Epilepsy Consortium on Complex Epilepsies, 2014); LPS, lipopolysaccharide.
morphologically activated (CD11b-positive area, hippocampus: $mm^2$, sham, $0.09 \pm 0.01$; 1 week after SE, $1.67 \pm 0.48$, $P = 0.0002$, Mann–Whitney test; $n = 10–11$ mice) and proliferate by 2.0-fold on average within 1 week after SE as assessed in a different cohort of mice by analysis of Iba1-positive cells in the forebrain (number of cells, hippocampus: sham, $614.4 \pm 7.1$; 1 week after SE, $1347 \pm 68.6$, $P = 0.0011$, Mann–Whitney test; $n = 10–11$ mice).

First, we studied whether the thickness and volume of selected cortical brain regions were reduced, and those of the lateral ventricles increased (directions of change as predicted by the ENIGMA-Epilepsy findings in humans) in placebo (non-medicated)-diet-fed epileptic mice ($n = 10$) vs sham mice (not exposed to SE, $n = 16$) as assessed by post-mortem MRI (experimental design in Figure S1A). In the post-mortem MRI analysis (Figures 3A, S5 and S6), we also included additional placebo-diet-fed epileptic mice ($n = 8$) run in parallel with mice depicted in Figure 3C ($n = 10$). These additional mice were video-EEG monitored only in the terminal disease phase (Days 55–90), and their seizure frequency ($0.91 \pm 0.26$, $n = 8$) was similar to mice depicted in Figure 3C ($1.65 \pm 0.75$, $n = 10$; $P = 0.41$ by the Mann–Whitney test).

These additional epileptic mice were also included in the histopathological brain analysis (Figure 3B) and for behavioural testing (Figure 3D). We found that the lateral ventricles were enlarged by twofold ($P = 0.0006$ by analysis of variance [ANOVA] followed by Tukey’s test; Figure S5A); this effect was associated with a significant reduction in the volume of the entorhinal ($P = 0.043$; Figure S5E) and perirhinal ($P = 0.025$ by ANOVA followed by Tukey’s test; Figure S5F) cortices. No significant changes were observed in other brain areas such as the hippocampus, caudato-putamen and the thalamus, although their average volumes trended lower than the corresponding values in sham mice (Figure S5B–D). Notably, a significant reduction in the thickness of entorhinal ($P = 0.0001$ by ANOVA followed by Tukey’s test; Figure 3A) and perirhinal ($P = 0.046$ by ANOVA followed by Tukey’s test; Figure S6) cortices was also measured in the same mice.
FIGURE 3 Legend on next page.
Next, we measured brain region volumes and cortical thickness in mice fed with medicated diet, supplemented with PLX3397, in order to deplete microglia by >90% (Figure S7) during the initial disease development (i.e., until Day 7 after spontaneous seizure onset; experimental design in Figure S1A). Importantly, this decrease in microglia was induced transiently, because microglia re-populated the forebrain within 1 week after switching mice to a placebo non-medicated diet [32]. This protocol was followed in order to assess the impact of microglia activation in the initial phases of the disease on the structural brain changes detected in the epileptic mice. We found that the decrease in thickness of the entorhinal cortex of epileptic mice under placebo diet vs sham mice was prevented in mice that were depleted of microglia in the early disease phase (P = 0.022 vs placebo by ANOVA followed by Tukey's test; Figure 3A). This indicates that early microglia depletion prevented the entorhinal cortical thinning determined in the chronic disease phase. Microglia depletion did not affect the thinning of the perirhinal cortex (Figure S6) or the ventricle and subcortical volume changes occurring in epileptic mice (Figure S5).

Evaluation of neuronal cell number in the entorhinal cortex of epileptic mice receiving placebo diet showed a significant decrease in both neuronal cell density (P = 0.0001 vs sham by ANOVA followed by Tukey's test; Figure 3B) and their average cell body size (P = 0.037 vs sham by ANOVA followed by Tukey's test; Figure 3B). The reduction in cell density, but not of the average cell body size, in epileptic mice was prevented by microglia depletion in the early disease phase (P = 0.006 vs placebo diet by ANOVA followed by Tukey's test; Figure 3B). Similarly, microglia depletion affected the reduction in discrimination index (a measure of non-spatial memory deficit dependent on entorhinal cortex function) [33] observed in epileptic mice fed with placebo diet (P = 0.0004 epileptic mice vs sham by ANOVA followed by Tukey's test; P = 0.049 epileptic mice on the PLX3397 diet vs placebo diet by the Mann–Whitney test) (Figure 3D). The total exploration time of objects during the familiarisation phase did not differ in the various experimental groups (sham, 24.07 ± 2.6 s; SE + placebo, 28.4 ± 4.7 s; SE + PLX3397, 29.7 ± 5.9 s; P = 0.25 sham vs placebo; P = 0.5 SE + placebo vs SE + PLX3397). Notably, microglia depletion in the early disease phase did not modify the onset, duration and severity of SE (Figure S4A). Moreover, both frequency and duration of spontaneous seizures were unaltered by early microglia depletion as compared with placebo non-medicated diet-fed mice (Figure 3C; Figure S4C vs B).

**FIGURE 3** Effects of microglia depletion in the early disease phase on entorhinal cortex thickness and neuronal cell loss and on cognitive deficit in epileptic mice. The experimental design is depicted in Figure S1A. Grey symbols represent sham (n = 6–8) and epileptic mice fed with placebo diet (n = 8) run in parallel with experimental mice of (C) (see text for details). (A) Box-and-whisker plots depicting median, minimum, maximum and single values related to the entorhinal cortex thickness, as assessed by quantitative post-mortem magnetic resonance imaging (MRI) analysis performed in epileptic mice at the end of electroencephalography (EEG) monitoring (placebo are mice fed with non-medicated diet: n = 18; PLX3397 are mice fed with medicated diet supplemented with PLX3397; n = 7) and in sham mice (not exposed to status epilepticus: n = 16). MRI images depict representative slices showing the region of interest (ROI) used to quantify the cortical thickness. Four mice in the PLX3397 group did not undergo MRI analysis, and therefore, they were not included in the subsequent histological (B) and behavioural analyses (D). The white line within the ROI was manually drawn to measure the cortical thickness. **P = 0.0001 vs sham; *P = 0.022 vs placebo by analysis of variance (ANOVA) followed by Tukey's test. Scale bar: 1 cm. (B) Representative Nissl-stained sections (top row) of the entorhinal cortex in the experimental groups (top row; sham, n = 14; placebo, n = 15; PLX3397, n = 7), and the relative quantification of the number and the average size of Nissl-stained neurons (bottom row). Two sham and three placebo mice were excluded from the analysis due to poor quality of Nissl staining. Data are shown by box-and-whisker plots depicting median, minimum, maximum and single values of the number of spontaneous seizures/day and their average duration during Days 1–7, 8–15 and 55–90 from epilepsy onset (Day 1) in the placebo (n = 10) and PLX3397-supplemented diet (n = 11) experimental groups (protocol in Figure S1A). Friedman's two-way nonparametric ANOVA (P = 0.041) followed by post hoc multiple comparisons test with Bonferroni correction: P-values for Number of seizures/day: P = 0.363, Days 1–7; P = 0.339, Days 8–15; P = 0.965, Days 55–90; P-values for Seizures duration: P = 0.799, Days 1–7; P = 0.325, Days 8–15; P = 0.262, Days 55–90. Outliers were identified only for the Number of seizures/day in the placebo group (n = 1 in Days 1–7) and in the PLX3397 group (n = 2 in Days 8–15 and n = 2 in Days 55–90); however, their omission did not change the results of the primary statistical analysis; therefore, the values were not removed from the corresponding dataset (P-values for sensitivity analysis: P = 0.831, Days 1–7; P = 0.375, Days 8–15; P = 0.084, Days 55–90). (D) Novel object recognition test (NORT) in epileptic mice fed with placebo– (n = 13) or PLX3397–supplemented diet (n = 7), and sham controls (n = 13). Three sham and five placebo diet epileptic mice were excluded from the analysis because they showed a total exploration time < 6 s during the familiarisation phase. Memory was evaluated by measuring the discrimination index, which was calculated as time spent (seconds) exploring the familiar (F) and the novel (N) object as follows: (N – F)/(N+F). Data are shown by box-and-whisker plots depicting median, minimum, maximum and single values, differences significant at **P = 0.0004 vs sham by ANOVA followed by Tukey's test; *P = 0.049 vs placebo by the Mann–Whitney test.

4 | DISCUSSION

The epilepsies are complex conditions with multiple facets including various causes, differing responses to treatment and unpredictable outcomes. Most attention has been paid to causation and processes of epileptogenesis across the broad constituent spectrum of syndromes. In contrast, disease progression has not been a primary focus of research even though for some rare epilepsies (the developmental and epileptic encephalopathies [DEE]), the window of opportunity to ameliorate disease may be open for longer than expected, as disrupted patterns of gene expression last into adulthood [34]. Here, we show that across the broad spectrum of the more common epilepsies (specifically excluding DEE), gene expression-predicted microglial density...
spatially correlated with reduced cortical thickness; the related genes newly implicate innate immunity and, particularly, microglial activation, as contributors to the underlying cause of cortical thinning. We also show that this molecular signature of innate immunity activation is significantly enriched for a gene set already causally linked to seizure frequency in a mouse model of chronic epilepsy [27], though we note our model differs from the model in that study. Further, our data add new evidence supporting the general concept that microglial activation is associated with at least some of the structural changes seen in brain areas involved in seizure circuitry, in that microglial depletion in mice early during disease development can directly prevent associated cortical thinning in the entorhinal cortex. Notably, microglial depletion in mice also prevented neuronal cell loss in the entorhinal cortex, and this neuroprotective effect was associated with improvement of cognitive deficit measured by the non-spatial memory test, that is sensitive to entorhinal cortex function [33].

Furthermore, we tested the hypothesis that microglial/monocyte activation is a key modulator of the severity of epilepsy using both genetic and functional approaches. We used the availability of GWAS data for resistance to anti-epileptic drug treatment, a marker of disease severity, to investigate enrichment in heritability at genetic loci already known to influence the expression of genes involved in monocyte activation. We find a highly significant enrichment in the heritability of epilepsy severity amongst these immunomodulatory loci, despite the absence of a significant enrichment for heritability of epilepsy per se. Finally, in keeping with these observations, experimental microglial depletion timed to coincide with a period of epileptogenesis in a murine model of acquired epilepsy can prevent regionalised cortical thinning, but does not influence the eventual development of seizures themselves in our model. Data from the experimental model also demonstrate that the cortical thinning is at least partly due to reduced neuronal cell density and average neuronal size: reduction of neuronal density can be prevented by appropriately timed microglial depletion while neuronal size changes were not rescued, which may explain the observation that entorhinal volume changes are not completely prevented by microglial depletion. We, and others [35–40], find that activated microglia are present in excess in brain tissue from people with epilepsy, compared with brain tissue from healthy controls, providing evidence for translation to human epilepsies of our assertions from the experimental model data. We selected Iba1 as a robust immunomarker for microglia in formalin-fixed tissue [41]. Like HLA-DR and CD68, Iba1 labels all phenotypes of microglia from ramified and amoeboid forms to macrophages and is therefore suited to structural studies of normal cortex in the absence of focal pathology [42]. We recently reported increased Iba1 labelling in central autonomic cortical regions in SUDEP, which also associated with increased seizures prior to death [43]. Together, these findings separate important processes occurring in the course of the epilepsies and incriminate potentially modifiable microglial activation states in the hitherto largely ignored feature of cortical thinning in the common human epilepsies. Unsurprisingly, our results also suggest that other factors are likely to be involved, which we have not explored further yet.

Importantly, we note as limitations that we assume a high degree of similarity in the genetics of gene expression in monocytes and microglia and that the clue to the possible role for microglial activation in cortical thinning came from a cross-sectional study of chronic human epilepsy: although reduced cortical thickness correlated with disease duration [8], we could not distinguish whether the structural difference had developed at disease onset (e.g., with causation), during epileptogenesis, during the course of the disease or a combination of these epochs. Our multimodal data, and especially the experimental model results, allow us to begin to address this question. Notably, we used spatially resolved whole-brain gene expression data from healthy controls, rather than from the brains of people with epilepsy specifically to avoid confounding by secondary effects: some such effects (e.g., compensatory changes) may be worth exploring, but that was not our purpose here. The murine model in our study relates to early processes in epileptogenesis and shows a clear separation for microglial roles in cortical thinning and seizure occurrence, whereas data from other models relate to the chronic disease state and show an effect of microglial manipulation on seizure frequency in that chronic state [27, 44] (cortical thinning was not assessed in those models). The experimental and human data are not directly compatible, and we cannot test hypotheses arising from the chronic mouse model in data from human ENIGMA-Epilepsy. However, taken together, the data suggest that microglia may have multiple modifying roles during epileptogenesis and progression of disease across common human epilepsies, though we find no evidence that they contribute to the actual occurrence of these common forms of epilepsy (from either our human or murine data). That seizure frequency and cortical thinning may be separable processes adds to important epidemiological evidence that seizure frequency is not the only contributor to morbidity in people with a history of epilepsy [5]. Microglia have many roles in specific types of epilepsy, demonstrated clearly in a variety of animal models. Such roles include phagocytosis, which may link consumption of synapses with cognitive changes in long-term active epilepsy [45], providing another possible mechanism for actual loss of brain volume in epilepsy: ‘time is brain’ [46].

Dysregulation of innate immunity is considered possibly to contribute to brain pathology and seizures in some severe human epilepsies. Microglial activation is seen in Rasmussen's encephalitis and in tissue from epilepsies due to hippocampal sclerosis and mesial temporal lobe sclerosis, focal cortical dysplasia and tuberous sclerosis [35–39]. The latter two conditions are known to have genetic, rather than inflammatory, causes, but the extent of microglial activation in the chronic disease phase correlates with severity (seizure frequency) and disease duration in these studies [35, 39] and not just cause, pointing again to distinctions between processes related to the initial cause (e.g., genetic disorder) and others that manifest during active disease. Importantly, resected human brain tissue is only available from a few cases of a few types of epilepsies (mostly surgical specimens from MTLE and focal cortical dysplasia [47]), so that it is impossible to otherwise evaluate the role of microglia using neuropathological data in the majority of common human epilepsies, from which brain tissue cannot be obtained in life. Brain imaging in animal
models using a label (TSPO) for microglial activation shows dynamic upregulation during epileptogenesis, with persistent, although declining, activity in the chronic phase and correlation with spontaneous seizures [48]; in chronic human temporal lobe epilepsy, there is increased TSPO binding ipsilateral and contralateral to seizure foci [49] and in the interictal phases [50]. Using immunolabelling, we demonstrate that there is over-representation of activated microglia in human and experimental brain tissue, compared with controls. The animal data also highlight that microglia expansion in epileptic mice occurs in the entorhinal but not in perirhinal cortex, and this effect is mirrored in the rescue of cortical thinning by microglia depletion (Figure S3). However, neither TSPO imaging nor neuropathological study is realistically applicable to large numbers of people with epilepsy, especially common epilepsies, while MRI is providing a readily available means of evaluating clinical translation of the implications of our findings. We propose, using MRI-derived patterns and correlation with gene expression, that activated microglia-associated functions drive the important, but as yet largely neglected, phenotype of cortical thinning in a broad swathe of common human epilepsies. Subsequent experimental intervention in an animal model suggests that early manipulation of microglia has the capacity to rescue disease-related cortical thinning, neuronal cell loss and cognitive deficits, opening up new areas for attention and treatment in common human epilepsies. We note that other cell types and processes are also implicated; these also need consideration, and suggest the possibility of multiple players in cortical thinning: we have focussed on one cell type, which does not diminish the potential utility of its manipulation. Other processes and cell types will be the subject of future investigations.

Our results point to important roles for neuroinflammatory pathways and potentially specific molecular actors, such as IFN-γ. However, the diversity of microglial states and functions, and the complex, dynamic, interactions between neurons, astroglia and microglia, that at the very least can promote epileptogenesis [25] have yet to be fully resolved. Clinical translation of our key observation of the widespread role of microglial activation across the breadth of types of epilepsy into therapeutic options to prevent irreversible loss of brain substance will require definition of the time course of thinning in the different types of epilepsy. Translation will also require the development of safe, effective and tolerable treatments that target precise mechanisms without compromising immune surveillance of brain tissue, a need across diverse neurological disorders [51].

ACKNOWLEDGEMENTS

We thank Angela Richard-Londt, Francesca Launchbury and Matthew Ellis for assistance with human neuropathology data collection: Mojgansadat Borghi, Ilaria Lagorio and Yi Yao for assistance with data collection; and Rafal Kamiński and Jonathan van Eyll for helpful discussions. We thank Dr L. Porcu (Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy) for statistical advice.

A. Altmann holds a Medical Research Council eMedLab Medical Bioinformatics Career Development Fellowship. This work was supported by the Medical Research Council (grant number MR/L016311/1). M.R. holds a Medical Research Council Clinician Scientist Fellowship (grant number MR/N008324/1). R.H.R. was supported through the award of a Leonard Wolfson Doctoral Training Fellowship in Neurodegeneration. The work was supported by grants from the European Union (7th Framework Programme [FP7 Ideas: European Research Council] Grants 279062, EpiPGX and 602102, EPITARGET). This work was partly undertaken at UCLH Biomedical Research Centre/UCL, which received a proportion of funding from the Department of Health’s NIHR Biomedical Research Centres funding scheme. The Epilepsy Society through the Katy Baggott Foundation supports the Epilepsy Brain and Tissue Bank at UCL, and Epilepsy Research UK (ERUK) supports the Corsellis Epilepsy brain collection. The work was also supported by the Epilepsy Society, UK (C.L., S.M.S.), Associazione Italiana Contro L’Epilessia (FIRE-AICE) and Fondazione Antonio Carlo Monzino (A.V.) and National Institutes of Health (NIH) Grants R01 NS097719 (M.E.M.), U54 EB020403 (P.T.) and NIH/NINDS R01 NS065838 (C.R.M.).

CONFLICT OF INTEREST

C.D.W. is now an employee of Biogen Research and Early Development (Cambridge, MA 02142, USA).

ETHICS STATEMENT

The project has ethical approval (under NRES 17/SC/0573), and post-mortem epilepsy cases had research consent, compliant with the UK Human Tissue Act 2014. Furthermore, in accordance with the ARRIVE guidelines, procedures involving animals and their care were conducted in conformity with the institutional guidelines that are in compliance with national (D.L. n.26, G.U. March 4, 2014) and international guidelines and laws (EEC Council Directive 86/609, OJ L 358, 1, December 12, 1987, Guide for the Care and Use of Laboratory Animals, U.S. National Research Council, 1996) and were reviewed and approved by the intramural ethical committee.

AUTHOR CONTRIBUTIONS

A. Altmann, M.R., A.V. and S.M.S. conceived and designed the research and wrote the paper. Authors J.A. to J.Z. and C.D.W., P.T., A. Altmann, M.R., A.V. and S.M.S. contributed to generation and analysis of human neuroimaging data as part of ENIGMA-Epilepsy working group, which is co-ordinated by C.R.M. and S.M.S., with overall leadership of the ENIGMA consortia by P.T. A. Altmann analysed AIBS data. C.L. and S.M.S. contributed to generation and analysis of human data. All authors contributed to the editing of the manuscript.

DATA AVAILABILITY STATEMENT

The complete normalised microarray gene expression data from the Allen Institute for Brain Science that support the findings of this study are available from the institute’s website at http://human.brain-map.org/static/download. The eQTL summary statistics on state-specific
monocytes that support the findings of this study are available in the supplementary tables at DOI: 10.1126/science.1246949. The summary results from the EpiPGX GWAS data that support the findings of this study are available from http://www.epigad.org. Data from the experimental model that support the findings of this study are available from the corresponding author(s) upon reasonable request.

REFERENCES

35. Aronica E, Gorter JA, Redeker S, et al. Distribution, characterization and clinical significance of microglia in glioneuronal tumours from


SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.